Inventiva S.A. (IVA)Healthcare | Biotechnology | Daix, France | NasdaqGM
2.94 USD
-0.17
(-5.466%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 2.92 -0.02 (-0.020%) ⇩ (Oct. 16, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 8:54 a.m. EDT
Inventiva presents a classic value trap scenario where aggressive analyst targets clash with deteriorating reality. The company is reporting a severe contraction in revenue, down 76.7% year-over-year, and is burning cash with negative operating cash flow and free cash flow. Despite the 'strong buy' recommendation based on a theoretical recovery to a $15 price target, the business fundamentals are currently broken, with losses expanding and revenue shrinking. The stock has already corrected massively over the past five years, dropping nearly 66% cumulatively, yet it remains priced at a premium multiple of sales that implies future growth that isn't materializing. With no dividend to provide income and a balance sheet showing significant debt relative to equity, the risk-reward profile is skewed heavily against the buyer. The options market confirms this skepticism, with traders loading up on puts to hedge against further declines rather than betting on a quick turnaround. Until revenue growth turns positive and cash burn stabilizes, this remains a speculative hold with limited catalysts for a sustainable recovery. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.093862 |
| AutoARIMA | 0.093862 |
| MSTL | 0.094801 |
| AutoTheta | 0.113308 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 68.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.030 |
| Excess Kurtosis | -0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 235.228 |
| Revenue per Share | 0.009 |
| Market Cap | 694,488,768 |
| Forward P/E | -3.94 |
| Beta | 1.00 |
| Website | https://inventivapharma.com |
As of Oct. 10, 2026, 8:54 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive put volume and open interest relative to calls across multiple expirations. While there is some call activity at the $5 strike, the overwhelming majority of open interest sits in out-of-the-money puts, particularly for January 2027 where put volume exceeds call volume significantly. This suggests a market consensus expecting further weakness or a prolonged period of volatility rather than an imminent rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4280156 |
| Address1 | 50 rue de Dijon |
| All Time High | 19.064 |
| All Time Low | 1.53 |
| Ask | 4.45 |
| Ask Size | 4 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,794,710 |
| Average Daily Volume3 Month | 1,609,431 |
| Average Volume | 1,609,431 |
| Average Volume10Days | 2,794,710 |
| Beta | 0.999 |
| Bid | 4.55 |
| Bid Size | 1 |
| Book Value | 0.2803175 |
| City | Daix |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.94 |
| Current Ratio | 3.808 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.14 |
| Day Low | 2.905 |
| Debt To Equity | 235.228 |
| Display Name | Inventiva |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,790,625,600 |
| Earnings Call Timestamp Start | 1,790,625,600 |
| Earnings Timestamp | 1,790,625,600 |
| Earnings Timestamp End | 1,790,625,600 |
| Earnings Timestamp Start | 1,790,625,600 |
| Ebitda | -149,059,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.477 |
| Enterprise To Revenue | 271.712 |
| Enterprise Value | 667,325,824 |
| Eps Current Year | -0.67829 |
| Eps Forward | -0.74614 |
| Eps Trailing Twelve Months | -0.62 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0454 |
| Fifty Day Average Change | -1.1054001 |
| Fifty Day Average Change Percent | -0.27324864 |
| Fifty Two Week Change Percent | -42.80156 |
| Fifty Two Week High | 7.983 |
| Fifty Two Week High Change | -5.0429997 |
| Fifty Two Week High Change Percent | -0.6317174 |
| Fifty Two Week Low | 2.82 |
| Fifty Two Week Low Change | 0.120000124 |
| Fifty Two Week Low Change Percent | 0.042553235 |
| Fifty Two Week Range | 2.82 - 7.983 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 165,570,989 |
| Forward Eps | -0.74614 |
| Forward P E | -3.9402792 |
| Free Cashflow | -116,119,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 87 |
| Fullday Change | -0.18999982 |
| Fullday Change Percent | -6.1093187 |
| Fullday Price | 2.94 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.78257006 |
| Gross Profits | 1,922,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.37333 |
| Implied Shares Outstanding | 236,220,651 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. |
| Long Name | Inventiva S.A. |
| Market | us_market |
| Market Cap | 694,488,768 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_273516426 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -247,723,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 811,282,193 |
| Number Of Analyst Opinions | 10 |
| Open | 3.14 |
| Operating Cashflow | -96,597,000 |
| Operating Margins | -53.37318 |
| Phone | 33 3 80 44 75 00 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.68027145 |
| Post Market Price | 2.92 |
| Post Market Time | 1,792,194,794 |
| Previous Close | 3.11 |
| Price Eps Current Year | -4.3344293 |
| Price Hint | 4 |
| Price To Book | 10.488108 |
| Price To Sales Trailing12 Months | 282.7723 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.733 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -5.46623 |
| Regular Market Day High | 3.14 |
| Regular Market Day Low | 2.905 |
| Regular Market Day Range | 2.905 - 3.14 |
| Regular Market Open | 3.14 |
| Regular Market Previous Close | 3.11 |
| Regular Market Price | 2.94 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 4,852,207 |
| Return On Assets | -0.42685002 |
| Return On Equity | -9.89052 |
| Revenue Growth | -0.767 |
| Revenue Per Share | 0.009 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 236,220,651 |
| Shares Percent Shares Out | 0.0353 |
| Shares Short | 8,346,026 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,684,862 |
| Short Name | Inventiva S.A. - American Depos |
| Short Percent Of Float | 0.0374 |
| Short Ratio | 4.2 |
| Source Interval | 15 |
| Symbol | IVA |
| Target High Price | 26.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 15.2 |
| Target Median Price | 14.0 |
| Total Cash | 166,127,008 |
| Total Cash Per Share | 0.703 |
| Total Debt | 138,788,992 |
| Total Revenue | 2,456,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.958675 |
| Two Hundred Day Average Change | -2.0186749 |
| Two Hundred Day Average Change Percent | -0.40709966 |
| Type Disp | Equity |
| Volume | 4,852,207 |
| Website | https://inventivapharma.com |
| Zip | 21,121 |